- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Bio-Thera Solutions' Biosimilar Adalimumab Launches in China
It is the first adalimumab biosimilar approved by the China National Medical Products Administration.
Bio-Thera Solutions said Friday that Qleti, a biosimilar adalimumab referencing Humira, is now available in China.
It is the first adalimumab biosimilar approved by the China National Medical Products Administration (NMPA) and is authorized for the treatment of rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis.
Bio-Thera's said it is the first of its biosimilars to receive regulatory approval and is the second biosimilar approved in China by the NMPA.
Bio-Thera announced in July 2019 that the biosimilar, BAT1406, had met its primary end point of equivalent efficacy to reference adalimumab in a phase 3 trial conducted in patients with active ankylosing spondylitis.
The application submitted to the regulatory authorities included a comprehensive data package that consists of analytical, preclinical, and clinical data. The clinical studies included a trial that investigated pharmacokinetic and pharmacodynamic data, as well as the phase 3 study in AS.
The drug maker is also developing biosimilar candidates of bevacizumab, tocilizumab, ustekinumab, and golimumab.
“The commercial launch of Bio-Thera’s first approved product is an enormous milestone for the company," said Shengfeng Li, PhD, chief executive officer of Bio-Thera Solutions, in a statement. "It demonstrates that Bio-Thera Solutions is a fully-integrated pharmaceutical company, able to take a product developed in our labs, through the clinic, through regulatory approval and now to the market. Bio-Thera is committed to bringing additional biosimilar and innovative products to the market in China and around the world."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
April 5th 2025High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
